Weight-Loss shot may boost success of common heart procedure
NCT ID NCT07389941
Summary
This study is testing if taking the weight-loss medication semaglutide before a standard heart procedure (catheter ablation) leads to better long-term control of atrial fibrillation (AFib) in people who are obese. It will involve 240 adults with symptomatic AFib who are scheduled for their first ablation procedure. Researchers want to see if pre-treatment helps patients stay free of irregular heart rhythms for a full year after the procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.